MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2024.
Highlights:
“Our second quarter 2024 results continue to demonstrate market traction for our Aquadex ultrafiltration therapy, with revenue growth driven by steady increases in consumables utilization, particularly in Critical Care and Heart Failure, supported by our growing body of clinical evidence that highlights the benefits of Aquadex for patients experiencing fluid overload who have not responded to traditional diuretic treatments. Of note, our higher margin consumables business continues to fuel manufacturing efficiencies, resulting in strong gross margin gains compared to the year ago period,” said Nestor Jaramillo, President and CEO of Nuwellis. “Bolstering our positive momentum in 2024, we are also excited to now expand our Pediatric product offerings with QUELIMMUNE™, providing our growing Pediatric network with a new therapy for acute kidney injury (AKI) and sepsis. This novel therapy comes to Nuwellis from our exclusive license and distribution agreement with SeaStar Medical Holding Corporation.”
Second Quarter 2024 Financial Results
Revenue for the second quarter of 2024 was $2.2 million, a 6% increase compared to the prior-year quarter. The year-over-year increase is attributable to a 30% increase in heart failure and critical care consumables utilization. Pediatrics had a 25% decline in utilization due to patient census.
Gross margin was 67.2% for the second quarter of 2024, compared to 55.3% in the prior-year quarter. The increase was primarily due to higher manufacturing volumes of consumables in the current year period and lower fixed overhead manufacturing expenses.
Selling, general and administrative expenses (SG&A) for the second quarter of 2024 decreased to $3.2 million, compared to $4.7 million in the prior-year quarter. The decrease in SG&A expense was primarily realized through efficiency initiatives enacted in the second half of 2023.
Second quarter research and development (R&D) expenses were $558 thousand, compared to $1.5 million in the prior-year quarter. The decrease in R&D expense was primarily due to reduced consulting fees and compensation-related expenses.
Total operating expenses for the second quarter of 2024 were $3.8 million, a 38% decrease compared to $6.2 million in the prior-year quarter as we continue to realize savings from operating efficiency initiatives enacted in the second half of 2023.
Operating loss for the second quarter of 2024 decreased to $2.3 million compared to an operating loss of $5.0 million in the prior-year quarter.
Net loss attributable to common shareholders for the second quarter of 2024 was $7.7 million, or a loss of $18.85 per basic and diluted common share, compared to a net loss attributable to common shareholders of $4.8 million, or a loss of $127.65 per basic and diluted common share in the prior-year quarter.
As of June 30, 2024, the Company had no debt, cash and cash equivalents of approximately $1.0 million, and approximately 516 thousand common shares outstanding. On July 25, Nuwellis closed a registered direct offering and concurrent private placement with gross proceeds of $2.0 million before deducting placement agent fees and other offering expenses.
Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-267-6316 (U.S) or 1-203-518-9783 (international) and using the conference ID: NUWEQ2. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2024 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | |||||||||||||||||||||
| June 30, 2024 | December 31, 2023 | ||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||
| ASSETS | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Cash and cash equivalents | $ | 1,023 | $ | 3,800 | |||||||||||||||||
| Accounts receivable | 1,292 | 1,951 | |||||||||||||||||||
| Inventories, net | 1,967 | 1,997 | |||||||||||||||||||
| Other current assets | 544 | 461 | |||||||||||||||||||
| Total current assets | 4,826 | 8,209 | |||||||||||||||||||
| Property, plant and equipment, net | 630 | 728 | |||||||||||||||||||
| Operating lease right-of-use asset | 613 | 713 | |||||||||||||||||||
| Other assets | 120 | 120 | |||||||||||||||||||
| TOTAL ASSETS | $ | 6,189 | $ | 9,770 | |||||||||||||||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Accounts payable and accrued liabilities | $ | 3,028 | $ | 2,380 | |||||||||||||||||
| Accrued compensation | 706 | 525 | |||||||||||||||||||
| Current portion of operating lease liability | 226 | 216 | |||||||||||||||||||
| Other current liabilities | 56 | 51 | |||||||||||||||||||
| Total current liabilities | 4,016 | 3,172 | |||||||||||||||||||
| Common stock warrant liability | 8,579 | 2,843 | |||||||||||||||||||
| Operating lease liability | 428 | 544 | |||||||||||||||||||
| Total liabilities | 13,023 | 6,559 | |||||||||||||||||||
| Commitments and contingencies | |||||||||||||||||||||
| Mezzanine Equity | |||||||||||||||||||||
| Series J Convertible Preferred Stock as of June 30, 2024 and December 31, 2023, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 88 and 11,950, respectively | 2 | 221 | |||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||
| Series A junior participating preferred stock as of June 30, 2024 and December 31, 2023, par value $0.0001 per share; authorized 30,000 shares, none outstanding | — | — | |||||||||||||||||||
| Series F convertible preferred stock as of June 30, 2024 and December 31, 2023, par value $0.0001 per share; authorized 18,000 shares, issued and outstanding 127 shares | — | — | |||||||||||||||||||
| Preferred stock as of June 30, 2024 and December 31, 2023, par value $0.0001 per share; authorized 39,352,000 shares, none outstanding | — | — | |||||||||||||||||||
| Common stock as of June 30, 2024 and December 31, 2023, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 515,744 and 162,356, respectively | — | — | |||||||||||||||||||
| Additional paid‑in capital | 292,887 | 290,647 | |||||||||||||||||||
| Accumulated other comprehensive income: | |||||||||||||||||||||
| Foreign currency translation adjustment | (42 | ) | (31 | ) | |||||||||||||||||
| Accumulated deficit | (299,681 | ) | (287,626 | ) | |||||||||||||||||
| Total stockholders’ equity (deficit) | (6,836 | ) | 2,990 | ||||||||||||||||||
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 6,189 | $ | 9,770 | |||||||||||||||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts and weighted average shares outstanding) | ||||||||||||||||||||||
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||
| Net sales | $ | 2,194 | $ | 2,075 | $ | 4,051 | $ | 3,901 | ||||||||||||||
| Cost of goods sold | 720 | 928 | 1,386 | 1,687 | ||||||||||||||||||
| Gross profit | 1,474 | 1,147 | 2,665 | 2,214 | ||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||
| Selling, general and administrative | 3,236 | 4,664 | 7,842 | 10,154 | ||||||||||||||||||
| Research and development | 558 | 1,505 | 1,892 | 2,933 | ||||||||||||||||||
| Total operating expenses | 3,794 | 6,169 | 9,734 | 13,087 | ||||||||||||||||||
| Loss from operations | (2,320 | ) | (5,022 | ) | (7,069 | ) | (10,873 | ) | ||||||||||||||
| Other income (expense), net | 6 | 179 | (95 | ) | 302 | |||||||||||||||||
| Financing Expense | (5,607 | ) | — | (5,607 | — | |||||||||||||||||
| Change in fair value of warrant liability | 198 | — | 720 | (755 | ) | |||||||||||||||||
| Loss before income taxes | (7,723 | ) | (4,843 | ) | (12,051 | ) | (11,326 | ) | ||||||||||||||
| Income tax expense | (2 | ) | (2 | ) | (4 | ) | (4 | ) | ||||||||||||||
| Net loss | $ | (7,725 | ) | $ | (4,845 | ) | $ | (12,055 | ) | $ | (11,330 | ) | ||||||||||
| Deemed dividend attributable to Series J Convertible Preferred Stock | — | — | 541 | — | ||||||||||||||||||
| Net loss attributable to common shareholders | $ | (7,725 | ) | $ | (4,845 | ) | $ | (11,514 | ) | $ | (11,330 | ) | ||||||||||
| Basic and diluted loss per share | $ | (18.85 | ) | $ | (127.65 | ) | $ | (40.91 | ) | $ | (323.15 | ) | ||||||||||
| Weighted average shares outstanding – basic and diluted | 409,690 | 37,949 | 294,649 | 35,060 | ||||||||||||||||||
| Other comprehensive loss: | ||||||||||||||||||||||
| Foreign currency translation adjustments | $ | (2 | ) | $ | 1 | $ | (11 | ) | $ | (6 | ) | |||||||||||
| Total comprehensive loss | $ | (7,727 | ) | $ | (4,844 | ) | $ | (12,066 | ) | $ | (11,336 | ) | ||||||||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) | |||||||||||||||||||||
| Six months ended June 30 | |||||||||||||||||||||
| 2024 | 2023 | ||||||||||||||||||||
| Operating Activities: | |||||||||||||||||||||
| Net loss | $ | (12,055 | ) | $ | (11,330 | ) | |||||||||||||||
| Adjustments to reconcile net loss to cash flows used in operating activities: | |||||||||||||||||||||
| Depreciation and amortization | 151 | 169 | |||||||||||||||||||
| Stock-based compensation expense | 273 | 378 | |||||||||||||||||||
| Change in fair value of warrant liability | (720 | ) | 755 | ||||||||||||||||||
| Warrant financing costs | 5,607 | — | |||||||||||||||||||
| Net realized gain on marketable securities | — | (65 | ) | ||||||||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||||||||
| Accounts receivable | 659 | 230 | |||||||||||||||||||
| Inventory, net | 30 | (72 | ) | ||||||||||||||||||
| Other current assets | (395 | ) | (547 | ) | |||||||||||||||||
| Other assets and liabilities | 5 | (20 | ) | ||||||||||||||||||
| Accounts payable and accrued expenses | 829 | (856 | ) | ||||||||||||||||||
| Net cash used in operating activities | (5,616 | ) | (11,358 | ) | |||||||||||||||||
| Investing Activities: | |||||||||||||||||||||
| Proceeds from sale of marketable securities | — | 578 | |||||||||||||||||||
| Additions to intangible assets | — | (99 | ) | ||||||||||||||||||
| Purchases of property and equipment | (53 | ) | (64 | ) | |||||||||||||||||
| Net cash provided by (used in) investing activities | (53 | ) | | 415 | |||||||||||||||||
| Financing Activities: | |||||||||||||||||||||
| Issuance of common stock from offering | 2,403 | — | |||||||||||||||||||
| Proceeds from the exercise of Series J Convertible Preferred Warrants | 500 | — | |||||||||||||||||||
| Proceeds from ATM stock offerings, net | — | 2,108 | |||||||||||||||||||
| Net cash provided by financing activities | 2,903 | 2,108 | |||||||||||||||||||
| Effect of exchange rate changes on cash | (11 | ) | (6 | ) | |||||||||||||||||
| Net decrease in cash and cash equivalents | (2,777 | ) | (8,841 | ) | |||||||||||||||||
| Cash and cash equivalents - beginning of period | 3,800 | 17,737 | |||||||||||||||||||
| Cash and cash equivalents - end of period | $ | 1,023 | $ | 8,896 | |||||||||||||||||
Supplemental cash flow information
| Issuance of Series J Preferred Stock for exercise of Warrants | $ | 1,857 | $ | — | ||||
| Issuance of Common Stock for conversion of Series J Preferred Stock | $ | 1,535 | $ | — | ||||
| Deemed dividend on Series J Preferred Stock | $ | (541 | ) | $ | — | |||
| Common stock offering costs included in prepaids | $ | 306 | $ | — |
| Last Trade: | US$1.21 |
| Daily Change: | -0.03 -2.42 |
| Daily Volume: | 240,243 |
| Market Cap: | US$2.260M |
November 04, 2024 November 01, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
